Drugs / 2',3',5'-tri-O-acetyluridine
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT00060515 | — | mitochondrial disease | Repligen Corporation | Terminated | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | 2',3',5'-tri-O-acetyluridine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00060515 ↗ |
| Known as | RG2133 | “RG2133 (2',3',5'-tri-O-acetyluridine)” NCT00060515 ↗ |